Write in a clean editor, then format for Progress in Neurotherapeutics and Neuropsychopharmacology in one click — DocuGuru applies the official Cambridge University Press template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Progress in Neurotherapeutics and Neuropsychopharmacology is a peer-reviewed journal published by Cambridge University Press, covering Schizophrenia research and treatment, Treatment of Major Depression, Parkinson's Disease Mechanisms and Treatments.
| Publisher | Cambridge University Press |
|---|---|
| Reference style | Numbered Numbered — [1], [2] in the text [1] A. Smith, B. Jones, and C. Lee, A representative article title, Progress in Neurotherapeutics and Neuropsychopharmacology 12 (2023) 45–58.
Formats any DOI in the closest standard style — Progress in Neurotherapeutics and Neuropsychopharmacology has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | Schizophrenia research and treatment Treatment of Major Depression Parkinson's Disease Mechanisms and Treatments Alzheimer's disease research and treatments Attention Deficit Hyperactivity Disorder |
| ISSN | 1748-2321 |
| h-index | 6 |
| i10-index | 2 |
| Total citations | 142 |
| Top institutions publishing here | Neurobehavioral Systems |
| Journal website | journals.cambridge.org |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
ABSTRACT There is evidence for an association between vascular disease and depression, and in particular between cerebrovascular disease and depression, especially that occurring later in life. Among the diverse psychiatric diseases, the one which is most widely studied concerning the relationship with the vascular system, is depression. The risk relationship between depression and vascular events…
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
ABSTRACT Background : Tramiprosate (3-amino-1-propanesulfonic acid, 3APS, ALZHEMED™) is an investigational product candidate that is believed to reduce amyloid deposition in the brain by binding to soluble Aβ, thereby slowing or halting the progression of Alzheimer Disease (AD). Design and Methods : We assessed the safety, tolerability, and pharmacokinetic/pharmacodynamic profiles of tramiprosate in a randomized,…
